Composite Lymphoma after Treatment with Infliximab for Sarcoidosis and Ankylosing Spondylitis.

Haruhiko Furusawa, Sho Shimada, Atsushi Sawada, Keisuke Tanaka, Kouhei Yamamoto, Yasunari Miyazaki

Abstract readCase Reports

In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Concurrent cytomegalovirus iridocyclitis and vitreoretinal lymphoma in the same eye during long-term infliximab therapy: a case report.Journal of ophthalmic inflammation and infection · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haruhiko FurusawaDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.

Sho ShimadaDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.

Atsushi SawadaDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.

Keisuke TanakaDepartment of Hematology, Tokyo Medical and Dental University, Japan.

Kouhei YamamotoDepartment of Human Pathology, Tokyo Medical and Dental University, Japan.

Yasunari MiyazakiDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphoid proliferations and lymphomas associated with immune deficiency and dysregulation (LP/L-IDD) are rare entities associated with the use of immunosuppressive drugs (ISD) for autoimmune conditions. Composite lymphomas, featuring both B-cell and T-cell lymphomas, are infrequent, and their occurrence as LP/L-IDD is rare. We herein report the case of a 70-year-old man with right pleural effusion and lymphadenopathy, who was treated with infliximab for sarcoidosis and ankylosing spondylitis. A biopsy revealed a composite lymphoma of DLBCL and PTCL-NOS. CHOP chemotherapy led to significant remission. This case report emphasizes the need to consider lymphoma in patients with autoimmune diseases such as sarcoidosis and ankylosing spondylitis, especially those treated with ISDs.

Indexed as

InfliximabSarcoidosisSpondylitis, AnkylosingAgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinHumansLymphoma, Large B-Cell, DiffuseMalePrednisoneVincristineCyclophosphamideDoxorubicinInfliximabPrednisoneVincristineankylosing spondylitiscomposite lymphomaOIIA-LPDsarcoidosis

Identifiers

PMID38839334

DOI10.2169/internalmedicine.3274-23

PMCPMC11781915

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.